Drug Information

Drug General Information
Drug ID
D06PVA
Former ID
DNCL002643
Drug Name
Volociximab
Drug Type
Antibody
Indication Non-small cell lung cancer [ICD10:C33-C34] Phase 2 [521881]
Company
Abbott Laboratories
CAS Number
CAS 558480-40-3
Target and Pathway
Target(s) Integrin alpha-5/beta-1 Target Info [528465]
KEGG Pathway Phagosome
PI3K-Akt signaling pathway
Focal adhesion
ECM-receptor interaction
Hematopoietic cell lineage
Regulation of actin cytoskeleton
Bacterial invasion of epithelial cells
Shigellosis
Pertussis
Proteoglycans in cancer
MicroRNAs in cancer
Hypertrophic cardiomyopathy (HCM)
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Dilated cardiomyopathy
Reactome Elastic fibre formation
Fibronectin matrix formation
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Cell surface interactions at the vascular wall
Basigin interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Other semaphorin interactions
Localization of the PINCH-ILK-PARVIN complex to focal adhesions
CHL1 interactions
RHO GTPases Activate Formins
WikiPathways Focal Adhesion
Extracellular matrix organization
Elastic fibre formation
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Cell surface interactions at the vascular wall
References
Ref 521881ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
Ref 528465Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.